Rational optimization of a monoclonal antibody improves the aggregation propensity and enhances the CMC properties along the entire pharmaceutical process chain

• Main Authors: Joschka Bauer (Author), Sven Mathias (Author), Sebastian Kube (Author), Kerstin Otte (Author), Patrick Garidel (Author), Martin Gamer (Author), Michaela Blech (Author), Simon Fischer (Author), Anne R Karow-Zwick (Author)
• Format: Book
• Published: Taylor & Francis Group, 2020-01-01T00:00:00Z.
• Subjects: article
• Online Access: Connect to this object online.

The discovery of therapeutic monoclonal antibodies (mAbs) primarily focuses on their biological activity favoring the selection of highly potent drug candidates. These candidates, however, may have physical or chemical attributes that lead to unfavorable chemistry, manufacturing, and control (CMC) p...